Phase IV study (postmarketing surveillance) of Tarivid (ofloxacin) in China.
Institute of Clinical Pharmacology, Beijing Medical University, China.
J T
JT
Li
M
M
Yoshida
K
K
Nakatsuka
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002681:China; D017327:Clinical Trials, Phase IV as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D015242:Ofloxacin